

USSN: 10/730,334
Docket No. 3191-A

RECEIVED
CENTRAL FAX CENTER
NOV 06 2006

2. Amendments to the claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. *(Original)* A method, comprising:
 - (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant;
 - (b) administering a nonmyeloablative conditioning regimen to the patient; and
 - (c) transplanting hematopoietic cells to the patient.
2. *(Original)* The method of claim 1, wherein the step of administering a Flt3-L composition is selected from the group consisting of:
 - (a) administering the Flt3-L composition prior to transplanting hematopoietic cells to the patient;
 - (b) administering the Flt3-L composition concurrent with transplanting hematopoietic cells to the patient;
 - (c) administering the Flt3-L composition subsequent to transplanting hematopoietic cells to the patient; and
 - (d) any combination of (a)-(c).
3. *(Original)* The method of claim 1, further comprising administering a growth factor or cytokine.
4. *(Currently amended)* The method of claim 1, wherein the step of administering a nonmyeloablative conditioning regimen comprises radiotherapy. ~~is selected from the group consisting of:~~
 - ~~(a) radiotherapy;~~
 - ~~(b) chemotherapy;~~
 - ~~(c) immunosuppression; and~~
 - ~~(d) a combination of (a)-(c).~~
5. *(Original)* The method of claim 1, further comprising administering one or more immunosuppressants to the patient post-transplant.
6. *(Original)* The method of claim 1, further comprising administering adoptive immunotherapy post-transplant.

USSN: 10/730,334
Docket No. 3191-A

7. *(Original)* The method of claim 6, wherein the adoptive immunotherapy is a donor lymphocyte infusion.
8. *(Original)* A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant,
 - (b) administering nonmyeloablative conditioning regimen to the patient; and
 - (c) transplanting hematopoietic cells to the patient, wherein the hematopoietic cells are autologous hematopoietic cells.
9. *(Original)* The method of claim 8, wherein the step of administering a Flt3-L composition is selected from the group consisting of:
- (a) administering the Flt3-L composition prior to transplanting hematopoietic cells to the patient;
 - (b) administering the Flt3-L composition concurrent with transplanting hematopoietic cells to the patient;
 - (c) administering the Flt3-L composition subsequent to transplanting hematopoietic cells to the patient; and
 - (d) any combination of (a)-(c).
10. *(Original)* The method of claims 8, further comprising administering a growth factor or cytokine.
11. *(Original)* The method of claims 8, wherein the autologous cells are obtained from autologous bone marrow.
12. *(Withdrawn)* The method of claims 8, wherein the autologous cells are obtained from autologous peripheral blood.
13. *(Currently amended)* The method of claims 8, wherein the step of administering a nonmyeloablative conditioning regimen comprises radiotherapy, is selected from the group consisting of: _____
- ~~(a) radiotherapy;~~
 - ~~(b) chemotherapy;~~
 - ~~(c) immunosuppression; and~~
 - ~~(d) (a) a combination of (a) (c).~~

USSN: 10730,334
Docket No. 3191-A

14. *(Original)* The method of claim 8, further comprising administering one or more immunosuppressants to the patient post-transplant.
15. *(Original)* The method of claim 8, further comprising administering adoptive immunotherapy post-transplant.
16. *(Original)* The method of claim 15, wherein the adoptive immunotherapy is a donor lymphocyte infusion.
17. *(Withdrawn)* A method, comprising:
 - (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant,
 - (b) administering a nonmyeloablative conditioning regimen to the patient; and
 - (c) transplanting hematopoietic cells to the patient, wherein the hematopoietic cells are allogeneic hematopoietic cells.
18. *(Withdrawn)* The method of claim 17, wherein the step of administering a Flt3-L composition is selected from the group consisting of:
 - (a) administering the Flt3-L composition prior to transplanting hematopoietic cells to the patient;
 - (b) administering the Flt3-L composition concurrent with transplanting hematopoietic cells to the patient;
 - (c) administering the Flt3-L composition subsequent to transplanting hematopoietic cells to the patient; and
 - (d) any combination of (a)-(c).
19. *(Withdrawn)* The method of claim 17, further comprising administering a growth factor or cytokine.
20. *(Withdrawn)* The method of claims 17, wherein the allogeneic cells are obtained from allogeneic bone marrow.
21. *(Withdrawn)* The method of claims 17, wherein the allogeneic cells are obtained from allogeneic peripheral blood.

USSN: 10/730,334
Docket No. 3191-A

22. (*Withdrawn*) The method of claim 17, wherein the step of administering the a nonmyeloablative conditioning regimen is selected from the group consisting of:
- (a) radiotherapy;
 - (b) chemotherapy;
 - (c) immunosuppression; and
 - (d) a combination of (a)-(c).
23. (*Withdrawn*) The method of claim 17, further comprising administering one or more immunosuppressants to the patient post-transplant.
24. (*Withdrawn*) The method of claim 17, further comprising administering adoptive immunotherapy post-transplant.
25. (*Withdrawn*) The method of claim 24, wherein the adoptive immunotherapy is a donor lymphocyte infusion.